Skip to main content

#161778

TOV-2929D cell line

Cat. #161778

TOV-2929D cell line

Cat. #: 161778

Availability: 8-10 weeks

Organism: Human

Tissue: Derived from solid tumor of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Sauriol A et al. 2020. Cancers. 12(8):2222. PMID: 32784519

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: TOV-2929D cell line
  • Alternate name: TOV-2929D
  • Cancer: Gynaecologic cancer
  • Research fields: Cancer
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from solid tumor of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
  • Donor: Grade 3 – Stage IIIC; Mutations: TP53 Exon 7; Pre-treatment for ovarian cancer/ colon cancer 5 years before
  • Morphology: Characteristic flattened cobblestone-like appearance. Formed compact flat discs rather than spherical spheroids.
  • Growth properties: Adherent
  • Crispr: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from solid tumor of patient diagnosed with high-grade serous ovarian cancer. Sample taken from solid tissue of the ovary, specifically derived from samples of the right ovary
  • Production details: Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly.
  • Additional notes: Patient 2929 was age 77 at time of diagnosis with prior history of colorectal cancer. Patient was chemonaive at the time of sampling and sampling took place in 2006.

Handling

  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Temperature: 37° C
  • Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
  • Cultured in antibiotics: Amphotericin B and Gentamicin

References

  • Gaia-Oltean et al. 2021. Exp Ther Med. 21(3):243. PMID: 33603851 Canals Hernaez et al. 2020. J Immunother Cancer. 8(2):e001128. PMID: 33243933 Borzdzi?owska et al. 2022. Biomedicines. 11
  • 10(5):1116. PMID: 35625852 Meng et al. 2023. J Anim Sci. 3
  • 101:skad215. PMID: 37351870 Koni et al. 2020. Int J Mol Sci. 18
  • 21(20):7697. PMID: 33080952

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.